During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, spoke to the MM Hub about the recent advances in our understanding of myeloma progression.
The question remains for patients with smoldering MM: when should therapeutic intervention begin? Here, Irene Ghobrial discusses the need for more robust disease-characterizing and patient-defining criteria.
","author_name":"Scientific Education Support"}